GB
Georgina Bowyer
AstraZeneca, University of Cambridge, University of Oxford
Research areas: Medicine · Infectious Diseases · Immunotherapy and Immune Responses · Malaria Research and Control · SARS-CoV-2 and COVID-19 Research
0000-0002-2058-4045
Employment
-
AstraZeneca Associate Director2025 - Present
-
AstraZeneca Associate Principal Scientist2024 - 2025
-
AstraZeneca Senior Scientist2022 - 2024
-
University of Cambridge Post-Doctoral Researcher2019 - 2022
-
University of Oxford Research Assistant, Clinical Vaccine Trials2012 - 2018
Education
-
University of Oxford DPhil in Clinical Medicine2015 - Present
-
University of Cambridge BA - Natural Sciences2009 - 2012
Projects & Funding
Projects & funding information is unavailable.
Publications (35)
- Model‐Informed First‐In‐Human Dose Selection for AZD2796, a High‐Affinity Anti‐LILRB2 Antibody Save
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine Save
- Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge. Save
- Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials. Save
- R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study. Save
- Obesity Is Associated with Attenuated Tissue Immunity in COVID-19 Save
- Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Save
- Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence. Save
- Tissue Immunity in the Bladder. Save
- CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination Save
- Local and systemic responses to SARS-CoV-2 infection in children and adults. Save
- Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells Save
- Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine Save
- HLA‐E: exploiting pathogen‐host interactions for vaccine development Save
- First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. Save
- Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen - ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal. Save
- Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP Save
- Prime and target immunization protects against liver-stage malaria in mice Save
- Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. Save
- CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria Save